We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy
On June 11, 2026, the "AI-Driven Future: AI × Frontier Protein Technologies for Challenging Targets" summit co-hosted by Clickmab, Kactus Biosystems, and Sanyou Bio took place in Shanghai, exploring new AI-driven antibody R&D paradigms and industry practices.
ADCs, TCEs, CAR-T therapies, and other emerging modalities have increased demand for antibodies with specific functions and binding sites. They also present challenges involving difficult targets and complex proteins.
On June 11, 2026, Clickmab, Kactus Biosystems, and Sanyou Bio co-hosted the Shanghai summit "AI-Driven Future: AI × Frontier Protein Technologies for Challenging Targets, Launching a New Era of Drug Discovery."
Researchers and industry partners discussed how AI design, protein technologies, and experimental validation can work together to address these challenges.
Li Raoyi, Director of Strategic Partnerships at Clickmab
Li Raoyi, Director of Strategic Partnerships at Clickmab, gave a keynote titled "AI-Driven De Novo Antibody Design for Specific Epitopes."
In ADC, bispecific, and CAR-T programs, binding alone is often insufficient. The epitope, mechanism of action, and developability profile all influence a candidate’s value.
Clickmab’s Click.mAb. multi-agent AI antibody design platform combines a proprietary database of millions of paired antibody records with generative models, structure prediction, epitope analysis, and directed evolution. It supports design, optimization, and validation around specified functional epitopes.
In the presentation, Clickmab shared several representative project cases, covering initial discovery and subsequent optimization guided by biological function — with focused mutant recommendations and targeted optimization as core advantages, validating platform capabilities across multiple projects.
GPCR Agonist Optimization Project
CAR-T Project
De Novo Design, Affinity Maturation & Humanization Validation Cases
For innovative drug development, what truly matters is not obtaining more candidate molecules, but obtaining the right ones faster. As Li Raoyi shared: "What we aim to do is not use whatever we screen — but design whatever we need."
If AI is transforming antibody design, the success of challenging target development also requires high-quality experimental platforms and supply-chain collaboration. At this summit, industry experts shared latest practices from different perspectives.
Sanyou Bio · VP Hailiang Zheng
Introduced the AI-STAL and SAI-DA intelligent R&D platforms, showing how an "algorithm prediction—experimental validation—data feedback" closed loop drives AI from an assistive tool to a full R&D engine.
Kactus Biosystems · VP of Market Strategy Li Yunyan
Focused on complex proteins, sharing solutions for multi-pass transmembrane proteins, TCR-CD3 complexes, and Nanodisc display technology. She noted that complex-target capabilities are becoming a key competitive differentiator as ADCs and TCEs advance.
Hentenovo Bio · SVP Dr. Liu Songkai
Shared insights on developability research, demonstrating how sequence optimization, process development, and formulation studies improve candidate molecule stability and manufacturability.
KangKang Bio · CEO Dr. Jiang Weidong
Introduced the latest advances in Prodrug technology, sharing how innovative design improves the balance between efficacy and safety for complex disease treatment.
From AI design to protein tools, from experimental validation to CMC development, innovations across different stages together form a new ecosystem for innovative drug R&D.
Clickmab develops AI tools to help scientists design molecules around specific biological questions. Working with Sanyou Bio, Kactus Biosystems, and other partners, the team aims to connect computational design with experimental capabilities and advance therapeutics for challenging targets.
Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.